Microbiotica Announces Completion of Recruitment in its Phase 1b Trial (COMPOSER-1) of MB310, a Precision Microbiome Medicine, in Ulcerative Colitis Patients
Cambridge, UK – 4 August 2025: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that patient recruitment is complete in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients.
This international trial has recruited 29 adult patients at clinical centres in the UK, Austria, Bulgaria, Poland and Spain. Initial results are expected by the end of 2025.